Regained rights of rigosertib in greater China. On January 23, 2020, Onconova announced the termination of HanX license partnership due to HanX failing to make required payments under the terms of the agreement. The company has multiple other partnerships for rigosertib in various parts of the world including Knight Therapeutics for Canada, Specialised Therapeutics for Australia and New Zealand, Pint Pharma for Latin America and SymBio Pharmaceuticals for Japan and Korea. Given rigosertib prospects, we believe Onconova should be able to sign another partner in China.Read More >>